Research press release


Nature Biotechnology

Rapid response flu vaccine



Lothar Stitzたちが、マウスやフェレット、ブタにmRNAワクチンを接種して、この理論を検証したところ、市販のワクチンの場合と同等か、もっと効果的な免疫応答が誘発された。このmRNAワクチンには、他にも2つの利点がある。高温でも安定なことと、若齢マウスと高齢マウスでも効果があることである。もしもこの方法がヒトにも応用できれば、このような特性が、既存のインフルエンザワクチンの欠点を補ってくれるかもしれない。すなわち、新生児や高齢者でも十分な防御効果が得られ、また冷蔵保存のできない地域の住民も恩恵を受けられるかもしれない。

A vaccine comprising solely of messenger RNA protects animals against influenza infection, reports a study published online this week in Nature Biotechnology. If this approach proves effective in humans, it might allow flu vaccines to be designed and manufactured in weeks rather than months, making responses to pandemics much faster.

Existing influenza vaccines are produced in chicken eggs or cultured cells in a cumbersome, time-consuming process. This means that it can be challenging to provide an adequate supply of vaccines in the face of an emerging influenza pandemic. Messenger RNA-whose sequence can be easily altered to match the sequence of a new influenza strain-can be produced by a far simpler and quicker process and could prove a useful alternative.

Lothar Stitz and colleagues tested this theory by vaccinating mice, ferrets and pigs with an mRNA vaccine. They report that the resulting immune responses were similar or superior to those triggered by commercially available vaccines. The mRNA vaccines also possess two other advantages: stability at high temperature and efficacy in very young and very old mice. If this method can be transferred to humans, these features might address additional deficiencies of existing influenza vaccines, namely providing sufficient protection to infants, the elderly and those living in areas lacking refrigeration.

doi: 10.1038/nbt.2436


メールマガジンリストの「Nature 関連誌今週のハイライト」にチェックをいれていただきますと、毎週各ジャーナルからの最新の「注目のハイライト」をまとめて皆様にお届けいたします。